NGM Biopharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

NGM Biopharmaceuticals

04/05/2023 23:34

* NGM Biopharmaceuticals Inc  NGM.OQ  reported a quarterly
adjusted loss of 58 cents​​ per share for the quarter ended in
March. The mean expectation of seven analysts for the quarter
was for a loss of 52 cents per share.
    * Revenue fell 89.3% to $2.25 million from a year ago;
analysts
expected $6.14 million. 
    * NGM Biopharmaceuticals Inc's reported EPS for the quarter
was a
loss of 58 cents​.
    * The mean earnings estimate of analysts had fallen by
about 11.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * NGM Biopharmaceuticals Inc shares had fallen by 4.4% this
quarter and lost 22.3% so far this year.
    * The company reported a quarterly loss of $47.65 million.
    * Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 10:34 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.52          -0.58          Missed
 Dec. 31 2022      -0.51          -0.45          Beat
 Sep. 30 2022      -0.59          -0.59          Met
 Jun. 30 2022      -0.55          -0.59          Missed